Matches in SemOpenAlex for { <https://semopenalex.org/work/W6890951> ?p ?o ?g. }
- W6890951 abstract "Abstract Background Peripheral T-cell lymphoma (PTCL) is known to have an aggressive clinical course and be associated with poor survival. The International Prognostic Index (IPI) score and the Prognostic Index for T-cell lymphoma (PIT) have been suggested as methods to predict the prognosis of PTCL. Ferritin, the iron storage protein, is associated with chronic inflammation. Although higher levels of serum ferritin are detected in many cancer patients, the significance of elevated serum ferritin as a prognostic factor for lymphoma has yet to be established. Thus, our retrospective study aimed to examine the prognostic value of serum ferritin levels in PTCL. Patients and Methods Serum ferritin levels were evaluated in 78 patients with PTCL, who were treated with anthracycline-containing regimens in 8 institutions affiliated to the Yokohama City University Hematology Group between 1998 and 2011. Fourteen patients received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); 44 receivedpirarubicin, cyclophosphamide, vincristine, and prednisone (THP-COP); 3 received THP-COP followed by radiotherapy; 3 received up-front autologous peripheral blood stem cell transplantation; and 14 received THP-COP at 2-week intervals in a clinical trial. Results The study population comprised 50 male and 28 female patients with a median age of 64 years at the time of diagnosis (range, 16–83 years). With regard to the PTCL subtype, 39 patients had PTCL, not otherwise specified, and 39 had angioimmunoblastic T-cell lymphoma. Twelve patients had localized disease and 66 patients had advanced Ann Arbor stage lymphoma. Twenty-three patients had a poor Eastern Cooperative Oncology Group performance status (PS) of 2–4. B symptoms were present in 34 patients. Risk stratification according to the IPI was as follows: low risk, 9 patients; low–intermediate risk, 20 patients; high–intermediate (HI) risk, 30 patients; and high (H) risk, 19 patients. According to the PIT, 4 patients were categorized into group 1, 25 into, group 2 , 28 into, group 3, 21 into, as group 4. The median observation period for the surviving patients was 50 months. The median serum ferritin level was 183 ng/ml (range, 5–14,622 ng/ml). Factors associated with a poor overall survival (OS) in univariate analysis were HI and H risk status with regard to IPI (P = 0.024), assignment to group 3 or 4 with regard to PIT (P = 0.017), poor performance status (P< 0.001), and ferritin levels ≥ 300 ng/ml (P< 0.001). The 4-year OS rate of all 78 patients was 54%. The 4-year OS rate was poorer in patients with serum ferritin levels ≥300 ng/ml (n = 21) than in those with serum ferritin levels< 300ng/ml (n = 57; 22% vs. 65%; P< 0.001) (Figure). Multivariate analysis including each factor comprising the IPI (age, lactate dehydrogenase level, PS, Ann Arbor stage, and number of extranodal lesions), gender, bone marrow involvement, and serum ferritin level showed that poor PS (P = 0.002, relative risk [RR] 3.6) and a serum ferritin level ≥300 ng/ml (P = 0.014, RR 2.7) were independent risk factors for poor OS. Conclusion The serum ferritin level is a useful prognostic marker for PTCL. Disclosures: No relevant conflicts of interest to declare." @default.
- W6890951 created "2016-06-24" @default.
- W6890951 creator A5000236073 @default.
- W6890951 creator A5003303822 @default.
- W6890951 creator A5005587908 @default.
- W6890951 creator A5009422862 @default.
- W6890951 creator A5013695615 @default.
- W6890951 creator A5016907235 @default.
- W6890951 creator A5022918605 @default.
- W6890951 creator A5027783702 @default.
- W6890951 creator A5030305676 @default.
- W6890951 creator A5031542442 @default.
- W6890951 creator A5032187275 @default.
- W6890951 creator A5034618139 @default.
- W6890951 creator A5035692929 @default.
- W6890951 creator A5039144227 @default.
- W6890951 creator A5060782672 @default.
- W6890951 creator A5062040776 @default.
- W6890951 creator A5074616675 @default.
- W6890951 creator A5077627508 @default.
- W6890951 date "2013-11-15" @default.
- W6890951 modified "2023-09-28" @default.
- W6890951 title "Serum Ferritin Level As a Prognostic Marker For Peripheral T-Cell Lymphoma." @default.
- W6890951 doi "https://doi.org/10.1182/blood.v122.21.4326.4326" @default.
- W6890951 hasPublicationYear "2013" @default.
- W6890951 type Work @default.
- W6890951 sameAs 6890951 @default.
- W6890951 citedByCount "0" @default.
- W6890951 crossrefType "journal-article" @default.
- W6890951 hasAuthorship W6890951A5000236073 @default.
- W6890951 hasAuthorship W6890951A5003303822 @default.
- W6890951 hasAuthorship W6890951A5005587908 @default.
- W6890951 hasAuthorship W6890951A5009422862 @default.
- W6890951 hasAuthorship W6890951A5013695615 @default.
- W6890951 hasAuthorship W6890951A5016907235 @default.
- W6890951 hasAuthorship W6890951A5022918605 @default.
- W6890951 hasAuthorship W6890951A5027783702 @default.
- W6890951 hasAuthorship W6890951A5030305676 @default.
- W6890951 hasAuthorship W6890951A5031542442 @default.
- W6890951 hasAuthorship W6890951A5032187275 @default.
- W6890951 hasAuthorship W6890951A5034618139 @default.
- W6890951 hasAuthorship W6890951A5035692929 @default.
- W6890951 hasAuthorship W6890951A5039144227 @default.
- W6890951 hasAuthorship W6890951A5060782672 @default.
- W6890951 hasAuthorship W6890951A5062040776 @default.
- W6890951 hasAuthorship W6890951A5074616675 @default.
- W6890951 hasAuthorship W6890951A5077627508 @default.
- W6890951 hasConcept C121608353 @default.
- W6890951 hasConcept C126322002 @default.
- W6890951 hasConcept C2776694085 @default.
- W6890951 hasConcept C2776755627 @default.
- W6890951 hasConcept C2776802502 @default.
- W6890951 hasConcept C2778319317 @default.
- W6890951 hasConcept C2778476033 @default.
- W6890951 hasConcept C2778559949 @default.
- W6890951 hasConcept C2778720950 @default.
- W6890951 hasConcept C2779338263 @default.
- W6890951 hasConcept C2779429289 @default.
- W6890951 hasConcept C2779725641 @default.
- W6890951 hasConcept C2911091166 @default.
- W6890951 hasConcept C530470458 @default.
- W6890951 hasConcept C71924100 @default.
- W6890951 hasConcept C90924648 @default.
- W6890951 hasConceptScore W6890951C121608353 @default.
- W6890951 hasConceptScore W6890951C126322002 @default.
- W6890951 hasConceptScore W6890951C2776694085 @default.
- W6890951 hasConceptScore W6890951C2776755627 @default.
- W6890951 hasConceptScore W6890951C2776802502 @default.
- W6890951 hasConceptScore W6890951C2778319317 @default.
- W6890951 hasConceptScore W6890951C2778476033 @default.
- W6890951 hasConceptScore W6890951C2778559949 @default.
- W6890951 hasConceptScore W6890951C2778720950 @default.
- W6890951 hasConceptScore W6890951C2779338263 @default.
- W6890951 hasConceptScore W6890951C2779429289 @default.
- W6890951 hasConceptScore W6890951C2779725641 @default.
- W6890951 hasConceptScore W6890951C2911091166 @default.
- W6890951 hasConceptScore W6890951C530470458 @default.
- W6890951 hasConceptScore W6890951C71924100 @default.
- W6890951 hasConceptScore W6890951C90924648 @default.
- W6890951 hasLocation W68909511 @default.
- W6890951 hasOpenAccess W6890951 @default.
- W6890951 hasPrimaryLocation W68909511 @default.
- W6890951 hasRelatedWork W1710561286 @default.
- W6890951 hasRelatedWork W1978728938 @default.
- W6890951 hasRelatedWork W1987400036 @default.
- W6890951 hasRelatedWork W2095530643 @default.
- W6890951 hasRelatedWork W2096393559 @default.
- W6890951 hasRelatedWork W2151555749 @default.
- W6890951 hasRelatedWork W2338351021 @default.
- W6890951 hasRelatedWork W2411712926 @default.
- W6890951 hasRelatedWork W2460769302 @default.
- W6890951 hasRelatedWork W2531107185 @default.
- W6890951 hasRelatedWork W2548493054 @default.
- W6890951 hasRelatedWork W2554494327 @default.
- W6890951 hasRelatedWork W2556136813 @default.
- W6890951 hasRelatedWork W2561912807 @default.
- W6890951 hasRelatedWork W2591843640 @default.
- W6890951 hasRelatedWork W2598281577 @default.
- W6890951 hasRelatedWork W2794476713 @default.
- W6890951 hasRelatedWork W2966844544 @default.